Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
TWST affiliate reported resale notices under Form 144 for small, recent dispositions. The filing lists three resale transactions by Robert F. Werner: 1,693 shares for $79,079.70 on 02/23/2026, 246 shares for $11,420.85 on 03/06/2026, and 164 shares for $9,372.40 on 05/04/2026. The filing also lists multiple scheduled Restricted Stock Vesting items with dates and share counts (examples include 1,062 shares vesting 08/22/2024 and 977 shares vesting 02/22/2026).
Twist Bioscience Corp ownership update: William Blair Investment Management, LLC filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 5,269,718 shares of Common Stock, representing 8.6% of the class. The filer reports sole voting power over 4,836,983 shares and sole dispositive power over 5,269,718 shares. The filing is signed by the Chief Compliance Officer on 05/07/2026.
Twist Bioscience Corp officer Dennis Cho reported a small mandated share sale linked to tax withholding. On May 4, 2026, he sold 1,962 shares of common stock at $57.1488 per share to cover taxes due on vesting Restricted Stock Units. After this transaction, he directly holds 135,941 shares of Twist Bioscience common stock, and the filing notes these sales were required under the company’s equity incentive plan and were not discretionary trades.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 5,127 shares of Common Stock at an average price of $57.1488 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to vesting Restricted Stock Units under the company’s equity incentive plans and are described as non-discretionary "sell to cover" transactions.
Following this tax-related sale, Leproust directly holds 853,760 shares of Common Stock. She also holds an employee stock option that is exercisable for 64,950 shares of Common Stock at an exercise price of $67.8500 per share, with an expiration date of August 31, 2030.
Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 2,844 shares of common stock at an average price of $57.1488 per share. The footnote explains these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.
The filing states these “sell to cover” transactions are mandated by the issuer’s plan election and are not discretionary trades by the executive. After this tax-related sale, Finn directly holds 278,964 shares of Twist Bioscience common stock.
Twist Bioscience Corp SVP Paula Green reported an open-market sale of 1,116 shares of common stock at $57.1488 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. After the transaction, she directly holds 122,988 shares of Twist Bioscience common stock.
Twist Bioscience Corp’s Chief Accounting Officer Robert F. Werner reported a small, mandated share sale tied to equity compensation taxes. On May 4, 2026, he sold 164 shares of common stock at $57.1488 per share to cover tax withholding from vesting Restricted Stock Units.
The company’s equity incentive plan requires these “sell-to-cover” transactions, and the footnote states they are not discretionary trades by Werner. After this tax-related sale, he directly owns 54,635 shares of Twist Bioscience common stock.
Twist Bioscience reported strong top-line growth but remains unprofitable for the quarter ended March 31, 2026. Revenue rose 19% to $110.7 million, with DNA synthesis and protein solutions up 28% and NGS applications up 12%, lifting gross margin to 51.6% from 49.6%.
The company posted a quarterly net loss of $44.0 million and a six‑month loss of $74.5 million, driven partly by higher selling, general and administrative expenses and $7.2 million of litigation settlement costs, net of recoveries. Operating cash outflow was $42.4 million for the first half.
Twist ended the quarter with $171.7 million in cash, cash equivalents and short‑term investments and expects this to fund operations for at least one year. It also entered a $20.0 million co‑exclusive license for Invenra’s B‑Body bispecific antibody platform and a related $13.8 million equity investment to deepen its therapeutics discovery offerings.
Twist Bioscience reported strong top-line growth but remains unprofitable for the quarter ended March 31, 2026. Revenue rose 19% to $110.7 million, with DNA synthesis and protein solutions up 28% and NGS applications up 12%, lifting gross margin to 51.6% from 49.6%.
The company posted a quarterly net loss of $44.0 million and a six‑month loss of $74.5 million, driven partly by higher selling, general and administrative expenses and $7.2 million of litigation settlement costs, net of recoveries. Operating cash outflow was $42.4 million for the first half.
Twist ended the quarter with $171.7 million in cash, cash equivalents and short‑term investments and expects this to fund operations for at least one year. It also entered a $20.0 million co‑exclusive license for Invenra’s B‑Body bispecific antibody platform and a related $13.8 million equity investment to deepen its therapeutics discovery offerings.
TWST submitted a Rule 144 notice listing proposed and recent sales of common stock by Emily M. Leproust. The filing lists multiple sale dates and share counts tied to restricted stock vesting and open-market sales, with individual transactions on 02/23/2026, 03/06/2026, 03/20/2026, 04/21/2026, 04/22/2026, and a vesting entry on 05/01/2026.
The filing itemizes share quantities and dollar amounts for each date, indicating routine insider dispositions and a vesting event reported under Rule 144.
TWST submitted a Rule 144 notice listing proposed and recent sales of common stock by Emily M. Leproust. The filing lists multiple sale dates and share counts tied to restricted stock vesting and open-market sales, with individual transactions on 02/23/2026, 03/06/2026, 03/20/2026, 04/21/2026, 04/22/2026, and a vesting entry on 05/01/2026.
The filing itemizes share quantities and dollar amounts for each date, indicating routine insider dispositions and a vesting event reported under Rule 144.
TWST affiliate submitted a Form 144 notice to sell Common stock. The notice lists 1,116 shares of Common stock tied to restricted stock vesting dated 05/01/2026 and a broker designation at Fidelity Brokerage Services. The filing also reports four completed dispositions in the past three months totaling 41, (…) recent transactions by Paula Green on 02/17/2026, 02/23/2026, 03/06/2026, and 03/20/2026 with per‑trade proceeds shown in the excerpt.
TWST affiliate submitted a Form 144 notice to sell Common stock. The notice lists 1,116 shares of Common stock tied to restricted stock vesting dated 05/01/2026 and a broker designation at Fidelity Brokerage Services. The filing also reports four completed dispositions in the past three months totaling 41, (…) recent transactions by Paula Green on 02/17/2026, 02/23/2026, 03/06/2026, and 03/20/2026 with per‑trade proceeds shown in the excerpt.